Dietmar Berger; Chief Medical Officer; Gilead Sciences Inc Andrew Dickinson; Chief Financial Officer; Gilead Sciences Inc Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc Terence ...

Gilead's commercial success underscores the dedication ... a first-in-class capsid inhibitor that was recently recognized by science as 2024's breakthrough of the year. To put this in context ...

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full ... Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Dietmar Berger; and our ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

Gilead Sciences, Inc. GILD reported its fourth-quarter ... “From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025 ...

US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration approval, with a decision expected in mid-June, Gilead Sciences Inc. announced ...

With Gilead Sciences' long-acting lenacapavir unlocking ... help speed up access in more than 100 countries, Gilead's chief commercial officer Johanna Mercier pointed out on the call.

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...